Stem Cell Therapy

What Stem Cell and Cell-Based Therapy Means

Stem cell therapy is commonly used as a broad term for several very different cell-based treatments.

At Nucellin Orthopedic Clinic, autologous cell-based treatment means that cells or cell-containing preparations are obtained from your own body. Depending on the diagnosis and treatment plan, the source may be:

• Peripheral blood
• Bone marrow
• Adipose tissue

These treatments are not identical.

They differ in how the cells are collected, which cell populations are present, how the preparation is processed and how it is delivered. Two clinics may both use the term “stem cell therapy” while offering biologically different procedures.

For this reason, we explain:

• Where the cells or cell-containing preparation comes from
• How it is collected
• How it is processed
• Where it will be delivered
• Why that source has been selected
• What the treatment can and cannot reasonably achieve

The purpose is not to sell a label. It is to choose an appropriate treatment for a clearly identified clinical problem.

A Note on the Term “Stem Cell”

The term “stem cell” is often used loosely in medical marketing.

Bone marrow concentrate, adipose-derived cell preparations and blood-derived cell fractions are not biologically interchangeable. Some preparations contain several types of cells rather than a purified population of stem cells.

Even the scientific term MSC may refer to mesenchymal stromal cells rather than a uniform population of cells proven to behave as stem cells inside the human body.

The more useful questions are:

• What tissue was collected?
• Which cells are likely to be present?
• Was the preparation minimally processed or cultured?
• How many cells were obtained?
• Where will they be placed?
• What evidence supports that specific preparation for that specific condition?

At Nucellin, the source and intended purpose of the treatment are discussed before the procedure.

The Three Cell Sources We Consider

Blood-Derived Cell Therapy

Blood-derived cell therapy uses an autologous cell-containing preparation obtained from the patient’s own peripheral blood.

Depending on the collection and processing method, a blood-derived preparation may contain mononuclear cells, progenitor-cell populations and other circulating cells involved in immune and tissue-signalling processes.

This is biologically different from activated PRF.

Activated PRF is a platelet- and fibrin-based treatment intended to provide a sustained release environment for platelet-associated signalling factors. Blood-derived cell therapy is prepared through a different protocol intended to obtain and concentrate selected cellular fractions.

Blood-derived treatment is also different from bone marrow- or adipose-derived treatment. It should not be described as though all three contain the same cells in the same concentration.

Potential advantages may include:

• Collection without bone marrow aspiration or adipose harvesting
• A comparatively less invasive harvesting process
• Use of the patient’s own blood
• The possibility of local or protocol-specific administration in selected patients
• Shorter procedural recovery at the collection site

However, blood-derived cell treatment is not automatically the appropriate option for every joint, tendon or degenerative condition.

Published musculoskeletal evidence remains limited and includes early-stage studies using different peripheral blood preparations. Peripheral blood mononuclear-cell treatment, mobilised peripheral blood cell treatment and other blood-derived preparations should not be treated as interchangeable procedures.

Blood-derived cell treatment cannot guarantee:

• Regeneration of a completely normal joint
• Restoration of all lost cartilage
• Repair of a complete tendon or ligament rupture
• Permanent pain relief
• Prevention of future degeneration
• Avoidance of surgery

Suitability depends on the diagnosis, treatment target, exact preparation, expected cell composition and realistic treatment goals.

Bone Marrow-Derived Cell Therapy

Bone marrow-derived treatment uses an autologous preparation collected from the patient’s own bone marrow.

Bone marrow contains several cell populations, including haematopoietic cells, stromal progenitor cells, platelets and other signalling components.

A bone marrow aspirate or concentrate is not a pure collection of one type of stem cell. It is a mixed biologic preparation whose composition can vary according to:

• Harvest location
• Aspiration technique
• The amount collected
• Processing method
• Patient age and health
• Final cell concentration

Bone marrow-derived treatment may be considered for selected patients with symptomatic joint degeneration, focal cartilage-related conditions or other carefully identified musculoskeletal targets.

It cannot guarantee:

• Regeneration of all lost cartilage
• Restoration of normal joint space
• Repair of major mechanical instability
• Permanent pain relief
• Prevention of future surgery

The collection requires a bone marrow aspiration procedure, usually performed under local anaesthesia with appropriate imaging and sterile technique.

Expected benefits, harvest-site discomfort, procedural risks and alternative treatments are discussed before treatment.

Adipose-Derived Cell Therapy

Adipose-derived treatment uses a cell-containing preparation obtained from the patient’s own fat tissue.

Adipose tissue contains a heterogeneous population of stromal, vascular, immune and progenitor cells. The final composition depends on how the tissue is collected and processed.

Adipose-derived treatment is not simply a larger dose of bone marrow treatment. It is a biologically different preparation.

It may be considered for selected patients with:

• Symptomatic degenerative joint disease
• Chronic cartilage-related pain
• Selected tendon or soft-tissue degeneration
• Persistent functional limitation despite appropriate non-surgical treatment
• A clearly identified treatment target

Adipose-derived treatment requires a separate harvesting procedure. The treatment plan therefore includes assessment of:

• General health
• Bleeding and infection risk
• Harvest-site suitability
• The target joint or tissue
• Rehabilitation requirements
• Travel and recovery planning

Adipose-derived treatment cannot guarantee:

• Restoration of a young and normal joint
• Complete cartilage regeneration
• Repair of a fully ruptured tendon
• Permanent pain relief
• Avoidance of joint replacement or other surgery

Adipose-derived stromal vascular preparations contain mixed cellular populations rather than one uniform purified stem-cell type.

What the Treatment Is Intended to Do

Cell-based treatment should not be described as the direct construction of a completely new joint.

The intended effect is to support a more favourable biologic environment around a carefully selected tissue or joint.

Potential biologic actions under investigation include:

• Modulation of inflammatory signalling
• Interaction with immune cells
• Release of cell-signalling molecules
• Support of local tissue homeostasis
• Support of rehabilitation and load adaptation

These mechanisms are still being studied and may differ according to the cell source, preparation and target condition.

The cells are not working in isolation.

Treatment response is also affected by:

• The stage of structural degeneration
• Mechanical alignment
• Joint stability
• Muscle strength
• Metabolic health
• Smoking
• Sleep and recovery
• Activity level
• Rehabilitation
• The load repeatedly placed on the tissue

A biologic procedure cannot reliably overcome an uncontrolled mechanical problem, major instability or a joint that requires definitive surgery.

The Biologic Environment Matters

By the time many patients seek cell-based treatment, the painful tissue has already been adapting for months or years.

The body may compensate by:

• Guarding the painful area
• Reducing movement
• Shifting load to another joint
• Changing walking or lifting patterns
• Increasing muscular tension
• Avoiding certain activities

This helps explain why two patients with similar scans can function very differently.

Imaging shows structural change. It does not directly measure tissue capacity, muscle function, nervous-system sensitivity or the ability to tolerate daily load.

Cell-based treatment is therefore considered as one part of a broader plan rather than a replacement for diagnosis and rehabilitation.

The wider clinical approach is explained on our Regenerative Medicine page.

Where the Evidence Is Stronger and Where It Is Limited

Evidence for cell-based musculoskeletal treatment varies considerably according to:

• The condition being treated
• The source of the cells
• The processing method
• Whether the preparation is cultured or non-cultured
• The number and type of cells delivered
• The comparison treatment
• The rehabilitation programme
• The outcome being measured

The largest body of clinical research is in knee osteoarthritis.

Some studies report improvements in pain and function after autologous cell-based treatment. However, systematic reviews have found that the certainty of evidence may remain low or very low because of small studies, inconsistent preparations and differences in study design.

Evidence is generally less established for:

• Hip and ankle osteoarthritis
• Shoulder and elbow degeneration
• Partial tendon injuries
• Spinal disc conditions
• Blood-derived musculoskeletal cell preparations

Small early-stage studies of peripheral blood mononuclear cells have reported possible improvements in knee symptoms, but these findings do not establish that all blood-derived treatments are effective or equivalent. Larger controlled studies are still needed.

Cell-based treatment should therefore be presented as a selective option, not a universal cure.

Conditions We May Assess

Candidacy is decided after examination and imaging review rather than from a diagnosis name alone.

Knee osteoarthritis is one of the most common reasons patients ask about cell treatment.

More detailed information is available on our Stem Cell Therapy for Knees page.

How Treatment Is Planned

1. Consultation

Dr. Heejun Kim personally reviews:

• Your symptoms
• Functional limitations
• Previous treatment
• X-rays, MRI or ultrasound findings
• Medical history
• Activity goals
• The stage of degeneration
• Whether surgery may provide a more predictable result

The consultation can be conducted in English.

Dr. Kim trained in orthopedic surgery at Severance Hospital and previously worked as a Clinical Instructor at Severance Hospital.

The first decision is not which cell source to use.

It is whether cell-based treatment is appropriate at all.

2. Identification of the Treatment Target

A cell-based procedure should not be performed merely because an MRI shows degeneration.

The proposed target should match:

• The location of pain
• Physical examination findings
• Functional limitations
• Imaging findings
• The expected mechanism of treatment

The target may be a joint, tendon or other carefully selected musculoskeletal structure.

3. Selection of the Cell Source

The most appropriate source is selected after considering:

• Diagnosis
• Stage of disease
• Treatment target
• Previous procedures
• General health
• Desired level of treatment
• Harvest-related risks
• Available evidence
• Recovery and travel requirements

The most complex or expensive option is not automatically the best option.

4. Collection

Collection differs according to the selected treatment.

Blood-derived treatment

Blood is collected from a peripheral vein and processed according to the selected protocol.

Bone marrow-derived treatment

Bone marrow is aspirated from an appropriate harvest site under sterile conditions and local anaesthesia.

Adipose-derived treatment

A small amount of adipose tissue is collected through a planned harvesting procedure under appropriate anaesthesia and sterile conditions.

5. Preparation

The collected blood, marrow or adipose tissue is processed according to the selected protocol.

The exact preparation method matters because different methods produce different cellular compositions.

We explain what is being prepared rather than relying only on the general term “stem cell therapy.”

6. Image-Guided Delivery

When local treatment is planned, the preparation is delivered to the selected target using ultrasound or fluoroscopic guidance when appropriate.

Image guidance helps:

• Confirm the treatment location
• Improve placement accuracy
• Avoid nearby nerves and blood vessels
• Document the procedure

7. Rehabilitation and Load Management

The procedure is followed by an individual recovery and rehabilitation plan.

This may include:

• Temporary activity restriction
• Protection of the treated joint or tissue
• Gradual restoration of movement
• Strengthening
• Correction of excessive load
• Progressive return to exercise
• Follow-up assessment

A cell-based procedure does not replace rehabilitation.

Recovery Timeline

Recovery depends on:

• The cell source
• Harvest method
• Treatment location
• Stage of disease
• Number of areas treated
• Baseline health
• Rehabilitation plan

A general pattern may include the following.

The First Several Days

Patients may experience:

• Soreness at the treatment site
• Soreness at a bone marrow or adipose harvest site
• Temporary joint irritation
• Mild swelling
• Temporary reduction in activity

The amount of discomfort varies according to the procedure.

Weeks 1–6

The focus is usually on:

• Protecting the treated tissue
• Maintaining safe movement
• Avoiding excessive loading
• Gradually restoring daily activity
• Monitoring for adverse reactions

A lack of immediate symptom change does not automatically mean treatment failure.

Weeks 6–12

Rehabilitation may progress toward:

• Strength recovery
• Improved movement control
• Increased walking or exercise tolerance
• Gradual return to more demanding activity

Months 3–6

Where improvement occurs, it may become clearer over several months.

However, recovery is not always linear and the degree of improvement varies.

There is no guaranteed timeline or guaranteed response.

Follow-Up

Follow-up is arranged according to the diagnosis and procedure rather than by one rigid schedule for every patient.

Follow-up may include:

• Symptom review
• Functional assessment
• Strength and range-of-motion testing
• Rehabilitation adjustment
• Monitoring of harvest and injection sites
• Repeat imaging when clinically necessary

For international patients, remote follow-up may be used when clinically appropriate.

If You Are Travelling to Seoul

The number of days required in Seoul depends on:

• The selected cell source
• Whether a separate harvest procedure is required
• The number of treatment sites
• Anaesthesia requirements
• The need for post-procedure review
• Your flight schedule and general health

The assessment, procedure and travel plan should be agreed before flights or accommodation are booked.

Bone marrow- and adipose-derived procedures generally require more advance planning than a standard consultation or simple injection treatment.

International patients may send previous imaging and medical reports before arranging treatment.

Practical information is available on our International Patients page.

Why the Clinical Process Matters

The result of cell-based treatment does not depend only on the injected preparation.

It also depends on:

• Selecting the correct patient
• Identifying the correct target
• Choosing an appropriate cell source
• Recognising when surgery is more appropriate
• Preparing the tissue and joint
• Managing load after treatment
• Completing rehabilitation
• Providing structured follow-up

At Nucellin, the physician who assesses you is also involved in treatment planning, procedural decision-making and follow-up.

Continuity matters because the decision is often more important than the procedure itself.

Who May Be a Reasonable Candidate?

Cell-based treatment may be considered when:

• Pain has continued despite appropriate rehabilitation and conservative treatment
• Examination and imaging identify a plausible treatment target
• Joint or tissue degeneration is contributing to functional limitation
• There is no urgent surgical condition
• The patient understands the limits of current evidence
• The patient is willing to complete the rehabilitation plan
• Treatment goals are realistic

Patients with early or moderate degeneration may have different options from patients with advanced structural destruction.

Advanced degeneration is not assessed from the X-ray alone. Symptoms, function, joint alignment and the likelihood of benefit from surgery must also be considered.

When Cell-Based Treatment May Not Be the Right Answer

Cell-based treatment may not be appropriate when there is:

• Active infection
• Suspected tumour
• Uncontrolled bleeding risk
• A displaced fracture
• A complete tendon rupture requiring repair
• Severe ligament instability
• Progressive neurologic loss
• Severe spinal-cord or nerve compression
• Advanced joint destruction for which surgery offers a more predictable result
• Unrealistic expectations of complete structural regeneration
• Inability to follow the recovery and rehabilitation plan

Some patients need:

• Mechanical stabilisation
• Tendon or ligament repair
• Joint replacement
• Decompression surgery
• Rehabilitation alone
• Modification of daily load
• More time before an invasive treatment is considered

Saying that cell treatment is not appropriate is part of responsible regenerative medicine.

Risks and Limitations

Autologous treatment means that the preparation comes from your own body. It does not mean that the procedure is risk-free.

Potential risks may include:

• Pain
• Swelling
• Bruising
• Bleeding
• Infection
• Temporary worsening of symptoms
• Nerve or blood-vessel injury
• Harvest-site discomfort
• Anaesthesia-related complications
• Failure to achieve meaningful improvement
• Need for further treatment or surgery

The specific risks depend on whether the cells are collected from blood, bone marrow or adipose tissue.

The evidence, uncertainties, alternatives and financial cost should be discussed before treatment. International guidance emphasises transparency and avoidance of claims that exceed the available clinical evidence.

A Realistic View of Cell-Based Treatment

Cell-based therapy is not a way to create a completely new joint from one procedure.

It cannot reliably reverse decades of structural degeneration.

It cannot correct every mechanical problem.

It cannot guarantee that surgery will never be required.

Realistic goals may include:

• Reducing inflammatory irritation
• Improving pain
• Improving function
• Supporting rehabilitation
• Increasing tolerance for walking and exercise
• Treating a carefully identified joint or tissue target
• Delaying more invasive treatment when medically reasonable

The goal is not to promise regeneration.

The goal is to determine whether supporting the biologic environment can meaningfully improve the function of the patient in front of us.

International Patients

International patients can consult directly with Dr. Kim in English.

You may send or bring:

• X-rays
• MRI images
• Ultrasound images
• Medical reports
• Previous treatment records
• Medication information

Imaging is reviewed together with your symptoms and physical examination rather than interpreted in isolation.

Nucellin Orthopedic Clinic does not have an on-site MRI scanner. When MRI is medically appropriate, imaging can be arranged at a nearby radiology centre and reviewed with you.

Cell-based procedures require individual planning. The recommended cell source, number of days in Seoul, rehabilitation plan and written estimate are discussed before treatment.

Information about insurance and payment is available on the Insurance & Payment page.

To arrange an evaluation, please contact the clinic.

Start with an informed medical assessment, not a procedure.